DOCSLIB.ORG

Personal Care Skincare, Hair Care, Sunscreens, Colour Cosmetics, Toiletries

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Personal Care Skincare, Hair Care, Sunscreens, Colour Cosmetics, Toiletries PERSONAL CARE SKINCARE, HAIR CARE, SUNSCREENS, COLOUR COSMETICS, TOILETRIES 1000 PRODUCTS ENDLESS POSSIBILITIES REDOX HAS HAD AN AMAZING HISTORY OF GROWTH AND DEVELOPMENT IN THE YEARS SINCE IT WAS FOUNDED IN 1965... 2 PERSONAL CARE PERSONAL CARE ABOUT REDOX Established in 1965 in Sydney, Redox is a leading chemical The Redox labelling system for its packaged products is distributor active in the Australian, Malaysian, New Zealand unique – defining product types and hazard codes, Redox and United States markets. Our business specialises in batch numbers and barcodes. The system enables the providing customers with the widest possible range of incoming and outgoing deliveries to be quickly and easily quality chemicals, ingredients and raw materials sourced matched to their analysis results. Therefore, at any time, from the world’s best manufacturers. Redox customers can request a certificate of analysis/ conformity, either by fax or accompanying their delivery. Redox add value through its expert sourcing ability, This certificate contains all of the information required to efficient freight and warehousing network, stringent ensure full traceability and accurate matching with the quality systems, close customer service, leveraged analysis results of the incoming delivery. buying power and market knowledge. We look for long term partnerships, where shared values and common goals align for mutual benefit. Our relationships are open, innovative and based on teamwork. Let Redox become WE UNDERSTAND YOUR NEEDS your supply chain partner and start to enjoy the benefits tens of thousands of customers enjoy around the globe. To be healthy is to be happy and productive, it’s at the core of everyone’s hopes and aspirations and at Redox it’s an essential part of who we are. Our quality management systems allow seamless integration into our QUALITY clients businesses, providing the peace of mind that our clients crave. Maintaining quality of output is absolutely vital to every one of Redox’s customers. To achieve the required standards, they must be assured that the raw materials they purchase consistently maintain stipulated standards. EXTENSIVE RANGE OF QUALITY Redox is an ISO9001 certified company and relevant sites have HACCP and/or FSSC22000 Certification and PRODUCTS commit to continual improvement. In addition to regular Our careful selection of quality products from all internal inspections and constant updates to comply with the corners of the globe allow formulators in the regulatory issues, SAI Global limited conducts bi-annual Pharmaceutical and Nutraceutical sectors the freedom to audits. We are committed to the Chemistry Australia tailor their products and take advantage of the best new technologies and trends. Responsible Care program and the Code of Conduct to protect against the illicit use of chemicals and comply with all relevant environmental programs and occupational health and safety regulations. Redox are also Members of RELIABLE DELIVERY AND the Roundtable on Sustainable Palm Oil (RSPO), Sedex and subscribers to the EcoVadis Supplier Sustainability LOCAL REPRESENTATION Ratings platform. The Human Health sector demands reliability of supply and personal service, that’s why we have 11 regional sales Our quality assurance program ensures all customers offices across 4 countries with over 50 storage locations. receive relevant and timely information on the storage and It doesn’t matter if you are in Sydney or Kuala Lumpur, Los handling of chemicals, as well as information to protect the Angeles or Auckland you can be sure that friendly help is health and safety of employees and the environment. not far away. MEMBER OF THE FOLLOWING INDUSTRY ASSOCIATIONS: 3 PERSONAL CARE PRODUCT LINES SPECIALTIES PRODUCT CODES Retinyl Palmitate (Vitamin A Palmitate) VITAPP Allantoin ALLANT Salicylic Acid SAACID Aloe Vera ALVERA Sodium Ascorbyl Phosphate SOASPH Alpha Bisabolol ALBISA Sodium Hyaluronate SOHYAL Alpha Tocopheryl Acetate (Vitamin E) VITEAC Triclosan TRICLO Aluminium Chlorohydrate ALCHHY Vitamin K1 VITKAB Ammonium Thioglycolate AMTHGL Zinc Pyrithione ZIPYRI Benzalkonium Chloride KUAMCO Zinc Ricinoleate ZIRICI Beta Glucan BEGLUC Betaine BETAIN ADDITIVES Ceramides CERAMI 2-Bromo-2-Nitropropane-1,3 Diol BRNIPR Chlorhexidine Gluconate CHLDIS Ascorbyl Palmitate ASPALM Citronella Oil CITROO Benzaldehyde BENZAL Cosmetic Actives SOPOGL Benzoic Acid BEACID Cosmetic Phyto Actives COPHAC Benzyl Alcohol BEALCO Cosmetic Powders COPOWD BHT BUHYDR Cottonseed Meal COSEME Butyl Paraben BUTPAR Diatomaceous Earth DIEART Cetrimide CETMAB Dihydroxacetone DIHYAC Chloro Methyl Isothiazolinone CHMEIS D-Panthenol (Vitamin B5) VITBEA Dehydroacetic Acid DEHAAC Elastin ELASTI Diazolidinyl Urea DIAURE Erythrulose ERLOSE Disodium EDTA EDTADS Glycolic Acid 70% Cos Grade GLACIC DMDM Hydantoin DMDMHL Gum Rosin GUROSI Etidronic Acid PHOSPH Lactic Acid LAACID Ethyl Paraben ETPAHY Nicotinamide NIAMID Imidazolidinyl Urea IMIURE Magnesium Ascorbyl Phosphate MAASPH Iodopropyl Butylcarbonate IPBCAA Marine Collagen FISHCO Methyl Paraben METPAR Phytantriol PHYTAN P Chloro-M-Cresol PACHME Piroctone Olamine PIOLAM PCMX (Para Chloro Meta Xylenol) PACHXY Polypropylene Beads POPROP Potassium Sorbate POSORB Pumice Sand PUSAND Phenoxyethanol PHEETH Pyruvic Acid PYACID Preservative Blends PRESER Pyrethrum PYRETH Propyl Gallate PRGALL Retinol RETINO Propyl Paraben PROPAR 4 PERSONAL CARE 5 REDOX MAINTAINS THE HIGHEST QUALITY IN ITS SUPPLY OF BOTH PRODUCTS AND SERVICES. IT HAS BEEN CERTIFIED AS A QUALITY ENDORSED COMPANY SINCE 1993, ACKNOWLEDGING ITS CAPACITY TO CONTROL THE QUALITY OF ITS PRODUCTS. 6 PERSONAL CARE v Sodium Benzoate SOBENZ Isocetyl Palmitate ISOCPA EDTA Tetrasodium Salt EDTATS Isoparaffins ISOPAR Isopropyl Myristate ISPRMY CHEMICALS Isopropyl Palmitate ISPRPA AMP AMMEPR Lanolin LANOLI Bentonite SOBENT Lecithin SOLECI Borax BORASA Methyl Esters MELAUR Caustic Soda CASODA Microcrystalline Wax WAXMIC Corn Starch COSTAR Mineral Oils WHIOIL Citric Acid CIACID Myristic Acid MYRSAC Kaolin CLAYCH Octyl Palmitate OCPALM Hydrochloric Acid HYACID Octyl Stearate ETSTEA Hydrogen Peroxide HYPERD Oleic Acid OLACID Magnesium Carbonate MACARB Palm Wax PASTEA Magnesium Stearate MASTEA Paraffin Wax PARWAX Magnesium Sulphate MASULP PEG-75 Lanolin LANETH Monoethanolamine MONOET PEG high molecular weight POLOX Sodium Bicarbonate SOBICA Petroleum PEJELL Sodium Chloride SODCHL Polybutene POBUTE Sodium Hypochlorite SOHYCL Polyisobutene POISBU Talc TALCUM PPG-15 Stearyl Ether PPGMYR Titanium Dioxide TIDIOX Shea Butter SHBUTT Triethanolamine 99% TRETAN Silicone Wax SILWAX Urea UREATE Sodium Stearate SOSTEA Zinc Oxide ZIOXID Soy Wax SOYWAX Spermaceti Wax SPEWAX EMOLLIENTS Sucrose Cocoate SUGEST Almond Milk ALMILK Beeswax BEEWAX EMULSIFIERS Caprillic Capric Triglycerides CACATR Cetyl Phosphates CEPHOS Carnauba Wax CARWAX Emulsifying blends EMAGEN Candellila Wax CANWAX Ethylene Glycol Stearate (EGS) ETGLST Ceresine Wax CERWAX Glyceryl Stearate GLMOST Cetearyl Octanoate CESTET Hydroxystearic Acid HYSTEA Cetostearyl Alcohol CESTAL Isostearic Acid ISSTEA Cetyl Alcohol CEALCO Laureth-23 SUFFAU Cocoa Butter COCOBU Laureth-3 SUFFAR Coconut Fatty Acids COFAAC Laureth-6 SUFFAF Cyclomethicones SILDMC Laureth-7 SIUFFAM Emu Oil OILEMU Laureth-8 SUFFAH Hydrogenated Castor Oil CASHYD Lauric Acid LAUACI 7 Lauryl Alcohol LAALCO PVP POVIPY Nonoxynol-10 SUFNOI PVP/VA Copolymer Alcoholic Dispersion VIPYVE Nonoxynol-4 SUFNOX PVP/VA Copolymer Aqueous Dispersion VIPYVW Nonoxynol-9 SUFNOB PVP/VA Copolymer Powder VIPYVA Oleth series SUFOLH Quaternium-18 DOQUAT Palmitic Acid PAACID Quaternium-80 DIQUPO PEG series Dioleate POETDO Quaternium-98 IMQUAT PEG series Distearate POETST Silicone Conditioners SICOND PEG series Hydrogenated Castor Oil CAHYET Stearamidopropyl DimethylAmine STAMID PEG series Monooleate POETMO VP/MA/VI Copolymer VPMAVI PEG-7 Glyceryl Cocoate POETGC Polyglyceryl-4-Oleate POGLOL HUMECTANTS Polysorbate 20 POLSOR Acetamide MEA ACEMEA Polysorbate 60 POLSOR 1, 3 Butylene Glycol BUGLYC Polysorbate 80 POLSOE Dipropylene Glycol DIPGLY Silicone Emulsifiers SIEMUL Glycereth-26 ETGLYC Sodium Stearoyl Lactylate SOSTLA Glycerine GLYCER Sorbitan Laurate SORLAU Hexylene Glycol HEGLYC Sorbitan Oleate POLSOE Honey HONEMA Sorbitan Stearate SOMOST Polyethylene Glycol series POETGL Sorbitan Trioleate SOTRIO Propylene Glycol PRGLYC Stearic Acid STACID Sodium PCA SODPCA Stearyl Alcohol STALCH Sorbitol SORBIL Sulphonated Castor Oil CASSUL SOLVENTS HAIR CARE Acetone ACETON Acrylates Copolymer Dispersions BUACEL Diethyl Ether DETHER Acrylates Copolymer Powder BUACEM Dimethyl Ether DIMEET Behentrimonium Chloride BEHENT Dipentene DIPENT Behentrimonium Methosulphate BEMESU Ethoxydiglycol DIGLEE Capryl Pyrrolidone OCPYRR Cetrimonium Chloride CECHLO10 D-Limonene LIMONE Dicetyldimonium Chloride DICECH Ethyl Acetate ETACET Distearyldimonium Chloride DISTCH Ethyl Alcohol ETALCO Hydroxyethyl Cetyldimonium Phosphate CEDIHY Ethyl Alcohol - Denatured MESPIR Lauryl Pyrrolione DOPYRR Ethyl Lactate ETLACT Polyquaternium-11 VIDIME Gum Turpentine GUTURP Polyquaternium-16 MEVICH Iso Amyl Acetate ISAMAC Polyquaternium-10 POQUAT Isopentane ISOPEN Polyureythane (low VOC sprays) POURET Isopropyl Alcohol ISPRAL Polyvinylcaprolactum VICAPR Propylene Carbonate P RCARB 8 PERSONAL CARE SUNSCREENS Dodecyl Benzylsulphonic Acid (DDBSA) DOBENZ Benzophenone-1 DIHYBE Lauryl Dimethylamine Oxide LADIAM Benzophenone-2 TEHYBE Pearl Agent PEAGEN Benzophenone-3 HYMEBE Soap Chips/Noodles SOCHIP Benzophenone-4 HYMESA Sodium C14-C16 Olefin Sulphonate SOOLSU
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Survey and Risk Assessment of Chemical Substances in Deodorants
    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al
    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
    [Show full text]
  • Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su
    Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones By Ming-Hsiu Yang Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chairperson Ryan A. Altman Michael D. Clift Apurba Dutta Michael F. Rafferty Jon A. Tunge Date Defended: April 26, 2017 The Dissertation Committee for Ming-Hsiu Yang certifies that this is the approved version of the following dissertation: Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones Chairperson Ryan A. Altman Date Approved: April 26, 2017 ii Abstract Ming-Hsiu Yang Department of Medicinal Chemistry, April 2017 The University of Kansas Fluorine plays an important role in drug design, because of some unique features imparted by fluorine. The incorporation of fluorine into small molecules can modulate molecular physicochemical properties, metabolic stability, lipophilicity, and binding affinity to the target proteins. However, few fluorinated molecules are biosynthesized by enzymes. This means incorporating fluorine into the molecules relies on synthetic methods. Thus, efficient synthetic strategies to access the molecules bearing a variety of privileged fluorinated moieties are important for drug discovery. Fluoroalkenes are an isopolar and isosteric mimic of an amide bond with distinct biophysical properties, including decreased H-bond donating and accepting abilities, increased lipophilicity, and metabolic stability. Moreover, fluoroalkenes can also serve as probes for conducting conformational analyses of amides. These potential applications require the development of efficient methods to access fluoroalkenes. In chapter 2, a Shapiro fluorination strategy to access peptidomimetic fluoroalkenes is demonstrated.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
    [Show full text]
  • Review of the Regulation of Products at the Interface Between Cosmetics and Therapeutic Goods
    PO Box 100, Woden ACT 2606, Australia Review of the regulation of products at the interface between cosmetics and therapeutic goods 18 March 2005 Review of the regulation of products at the interface between cosmetics and therapeutic goods March 2005 Prepared for the TGA by David B Newgreen Review of the regulation of products at the interface between cosmetics and therapeutic goods CONTENTS ABBREVIATIONS ..........................................................................................................ii ACKNOWLEDGMENTS .............................................................................................. iii TERMS OF REFERENCE ..............................................................................................iv SUMMARY.....................................................................................................................vi RECOMMENDATIONS..................................................................................................x 1. INTRODUCTION ......................................................................................................13 2. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN AUSTRALIA AND NEW ZEALAND ....................................................................23 2.1 AUSTRALIA......................................................................................................23 2.2 NEW ZEALAND ...............................................................................................33 3. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Opinion of the Scientific Committee on Consumer Safety on O
    SCCS/1613/19 Final Opinion Version S Scientific Committee on Consumer Safety SCCS OPINION ON the safety of aluminium in cosmetic products Submission II The SCCS adopted this document at its plenary meeting on 03-04 March 2020 SCCS/1613/19 Final Opinion Opinion on the safety of aluminium in cosmetic products – submission II ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final versions SCCS members Dr U. Bernauer Dr L. Bodin (Rapporteur) Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven SCCS external experts Dr A. Koutsodimou Dr A. Simonnard Prof. W. Uter All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 16 December 2019 until 17 February 2020). Comments received during this time period are considered by the SCCS. For this Opinion, some changes occurred, in particular in sections 1, 3.2, 3.3.4.5, 3.3.8.1, 3.5, as well as in related discussion parts and conclusion (question 1). The list of references has also been updated.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids. It is notable that breast cysts, as for Antiperspiran breast cancers, start most frequently in the upper outer quadrant of the breast, which is the region closest to the site of underarm antiperspirant application. Mechanistic Copyright: © 2019 Philippa D Darbre. evidence is reviewed for a link between aluminium levels in breast tissue, cyst Clinical Dermatology: Research And Therapy. This is an open access article formation and development of breast cancer. If excessive use of antiperspirant is a distributed under the Creative cause of breast cysts, then reduction or cessation of use could provide a preventative Commons Attribution License, which or even treatment strategy. Furthermore, if cyst formation from antiperspirant use is permits unrestricted use, distribution, an indicator of increased risk for breast cancer, then reduction in use of antiperspirant and reproduction in any medium, provided the original work is properly could also provide a strategy for reducing breast cancer risk.
    [Show full text]
  • Queensland Poisons Information Centre Annual Report 2019
    Queensland Poisons Information Centre Annual Report 2019 13 11 26 www.childrens.health.qld.gov.au/poisonsinformationcentre Poisons Information Centre Queensland Children’s Hospital Pharmacy Department, Level 2 501 Stanley Street South Brisbane Qld 4101 Table of Contents Mission Statement ............................................................................................................................................................ 4 Services and Operation ..................................................................................................................................................... 4 Location ......................................................................................................................................................................... 4 Telephone Access .......................................................................................................................................................... 4 Hours of Operation ........................................................................................................................................................ 4 Website .......................................................................................................................................................................... 4 Personnel ....................................................................................................................................................................... 5 External Consultants .....................................................................................................................................................
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]